摘要
目的系统评价薄芝糖肽注射液治疗肺癌的有效性和安全性。方法计算机检索Cochrane图书馆、Medline、EMbase、中文科技期刊全文数据库(VIP)、中国期刊全文数据库(CNKI)、中国生物医学文献数据库(CBM)和万方数据在线知识服务平台,纳入有关薄芝糖肽注射液治疗肺癌的随机对照试验和半随机对照试验,根据Cochrane Reviewer’s Handbook 5.0评价标准和工具对纳入的研究进行方法学质量评价,并使用Rev Man 5.0软件进行统计分析。结果共纳入7个随机对照试验,共402名受试者。无研究提及失访,亦未做意向性分析。Meta分析结果表明薄芝糖肽注射液联合西医常规用药治疗肺癌总有效率(OR=1.93,95%Cl[1.22,3.07])优于常规治疗组,差异有统计学意义(P<0.05)。纳入的7篇研究报道的不良反应表现轻微。结论西医常规用药的基础上加用薄芝糖肽注射液可提高治疗肺癌的临床疗效。
Objective To evaluate the efficacy and safety of Bozhi Glycopeptide Injection in the treatment of lung cancer. Methods We searched the Cochrane library,Medline,EMbase,China biomedical literature database（ CBM）,Chinese PSTP（ VIP）,Chinese Journal Full-text Database（ CNKI） and Wanfang Data knowledge online service platform,Bozhi Glycopeptide Injection relevant randomized controlled trials for treatment of lung cancer and semi randomized controlled trials,according to Cochrane Reviewer＇s Handbook 5 the evaluation criteria and methods of the research into tools for quality evaluation,and statistical analysis was performed using Rev Man 5 software. Results A total of 7 randomized controlled trials involving 402 subjects were included. No study referred to the visit and no intention analysis was conducted. Meta analysis showed that the total effective rate（ OR = 1. 93,95%,Cl[1. 22,3. 07]） of Bozhi Glycopeptide Injection combined with western medicine for routine treatment of lung cancer was better than that of conventional treatment group,the difference was statistically significant（ P 0. 05）. The adverse effects of the 7 studies reported were mild. Conclusion Western Medicine on the basis of conventional use of Bozhi Glycopeptide Injection can improve the clinical efficacy of treatment of lung cancer.
出处
《临床合理用药杂志》
2018年第4期50-52,共3页
Chinese Journal of Clinical Rational Drug Use
关键词
薄芝糖肽注射液
肺癌
META分析
Bozhi Glycopeptide Injection
Lung cancer
Meta analysis
